(secondQuint)SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer.

 This stage I/II study is designed to evaluate the appropriate dose of S-1 plus fixed-dose of oxaliplatin (SOX regimen) for Patients with D2 resection of gastric cancer and survival of SOX regimen for stage II-III patients(AJCC 7th).

 To assess the efficacy, data on recurrence and survival will be collected from the time of enrollment until 3 years after surgery.

 To evaluate safety, data on adverse events will be collected from the time of enrollment until 1 year after surgery.

.

 SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer@highlight

The purpose of this study is to assess the safety and efficacy of S-1 plus oxaliplatin combination chemotherapy based on the adverse events and survival period by performing a phase I/II study of this combination in patients with D2 resection of gastric cancer.

